Porokeratosis Plantaris, Palmaris et Disseminata Caused by Con- genital Pathogenic Variants in the MVD Gene and Loss of Hetero­zygosity in Affected Skin

Authors

  • Sabine Jägle
  • Hazem A. Juratli
  • Geoffroy Hickman
  • Kira Süßmuth
  • Maria C. Boente
  • Julia Kopp
  • Peter Kirchmeier
  • Andreas Zimmer
  • Rudolf Happle
  • Emmanuelle Bourrat
  • Henning Hamm
  • Judith Fischer Institute of Human Genetics, Medical Center, Faculty of Medicine, University of Freiburg, DE-79106 Freiburg, Germany

DOI:

https://doi.org/10.2340/00015555-3753

Keywords:

mevalonate diphosphate decarboxylase gene, porokeratosis plantaris, palmaris et disseminata, linear porokeratosis, mosaicism, second hit, loss of heterozygosity

Abstract

Porokeratoses are a heterogeneous group of keratinization disorders. For linear porokeratosis and disseminated superficial actinic porokeratosis, a heterozygous pathogenic germline variant in a mevalonate pathway gene and a postzygotic second hit mutation present in affected skin have been shown to be the patho­genetic mechanism for the development of the lesions. However, the molecular mechanism leading to development of porokeratosis plantaris, palmaris et disseminata is not known. This study analysed a cohort of 4 patients with linear porokeratosis and 3 patients with porokeratosis plantaris, palmaris et disseminata, and performed mutation analyses of DNA extracted from blood samples and skin biopsies. All of the study patients carried the heterozygous germline variant c.70+5G>A in the MVD gene. Loss of heterozygosity due to a second hit mutation was found in affected skin of 3 patients with linear porokeratosis and 2 patients with porokeratosis plantaris, palmaris et disseminata. These results suggest that porokeratosis plantaris, palmaris et disseminata shares the same pathogenetic mechanism as other porokeratosis subtypes and belongs to the phenotypic spectrum of MVD-associated porokeratosis.

Downloads

Download data is not yet available.

References

Williams GM, Fillman EP. Porokeratosis. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2020 [cited 2020 Jun 8]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK532290/.

Happle R. Mosaicism in human skin: understanding nevi, nevoid skin disorders, and cutaneous neoplasia. Berlin: Springer, 2014: p. 145.

DOI: https://doi.org/10.1007/978-3-642-38765-4

Requena L, Requena C, Cockerell CJ. Benign epidermal tumors and proliferations. In: Bolognia JL, Schaffer JV, Cerroni L (editors). Dermatology. 4th edition. China: Elsevier, 2018: p. 1894-1916.

Metze D, Oji V. Palmoplantar keratodermas. In: Bolognia JL, Schaffer JV, Cerroni L, editors. Dermatology. 4th edition. China: Elsevier, 2018: p. 924-943.

Oji V, Metze D, Traupe H. Inherited disorders of cornification. In: Rook's textbook of dermatology, 4 Vol. Griffiths C, Barker J, Bleiker T, Chalmers R, Creamer D, editors. Hoboken, NJ: Wiley-Blackwell, 2016.

Happle R. Cancer proneness of linear porokeratosis may be explained by allelic loss. Dermatology 1997; 195: 20-25.

DOI: https://doi.org/10.1159/000245678

Guss SB, Osbourn RA, Lutzner MA. Porokeratosis plantaris, palmaris, et disseminata. A third type of porokeratosis. Arch Dermatol 1971; 104: 366-373.

DOI: https://doi.org/10.1001/archderm.1971.04000220024005

Shaw JC, White CR. Porokeratosis plantaris palmaris et disseminata. J Am Acad Dermatol 1984; 11: 454-460.

DOI: https://doi.org/10.1016/S0190-9622(84)70190-3

Neumann RA, Knobler RM, Gebhart W. Unusual presentation of porokeratosis palmaris, plantaris et disseminata. J Am Acad Dermatol 1989; 21: 1131-1133.

DOI: https://doi.org/10.1016/S0190-9622(89)70314-5

Patrizi A, Passarini B, Minghetti G, Masina M. Porokeratosis palmaris et plantaris disseminata: an unusual clinical presentation. J Am Acad Dermatol 1989; 21: 415-418.

DOI: https://doi.org/10.1016/S0190-9622(89)80049-0

Irisawa R, Yamazaki M, Yamamoto T, Tsuboi R. A case of porokeratosis plantaris palmaris et disseminata and literature review. Dermatol Online J 2012; 18: 5.

Marschalkó M, Somlai B. Porokeratosis plantaris, palmaris, et disseminata. Arch Dermatol 1986; 122: 890-891.

DOI: https://doi.org/10.1001/archderm.1986.01660200062016

Zhang S-Q, Jiang T, Li M, Zhang X, Ren Y-Q, Wei S-C, et al. Exome sequencing identifies MVK mutations in disseminated superficial actinic porokeratosis. Nat Genet 2012; 44: 1156-1160.

DOI: https://doi.org/10.1038/ng.2409

Zhang Z, Li C, Wu F, Ma R, Luan J, Yang F, et al. Genomic variations of the mevalonate pathway in porokeratosis. eLife 2015; 4: e06322.

DOI: https://doi.org/10.7554/eLife.06322

Happle R. Somatic recombination may explain linear porokeratosis associated with disseminated superficial actinic porokeratosis. Am J Med Genet 1991; 39: 237-237.

DOI: https://doi.org/10.1002/ajmg.1320390229

Atzmony L, Khan HM, Lim YH, Paller AS, Levinsohn JL, Holland KE, et al. Second-hit, postzygotic PMVK and MVD mutations in linear porokeratosis. JAMA Dermatol 2019; 155: 548-555.

DOI: https://doi.org/10.1001/jamadermatol.2019.0016

Kubo A, Sasaki T, Suzuki H, Shiohama A, Aoki S, Sato S, et al. Clonal expansion of second-hit cells with somatic recombinations or C>T transitions form porokeratosis in MVD or MVK mutant heterozygotes. J Invest Dermatol 2019; 139: 2458-2466.e9.

DOI: https://doi.org/10.1016/j.jid.2019.05.020

Atzmony L, Choate KA. Second-hit somatic mutations in mevalonate pathway genes underlie porokeratosis. J Invest Dermatol 2019; 139: 2409-2411.

DOI: https://doi.org/10.1016/j.jid.2019.07.723

Wei SC, Yang S, Li M, Song YX, Zhang XQ, Bu L, et al. Identification of a locus for porokeratosis palmaris et plantaris disseminata to a 6.9-cM region at chromosome 12q24.1-24.2. Br J Dermatol 2003; 149: 261-267.

DOI: https://doi.org/10.1046/j.1365-2133.2003.05461.x

Goebeler M, Bröcker E-B, Hamm H. Keratotic plaques on the left trunk area and all extremities: porokeratosis. Arch Dermatol 2006; 142: 1059-1064.

DOI: https://doi.org/10.1001/archderm.142.8.1059-c

Happle R. Porokeratosis palmaris, plantaris et disseminata vs. porokeratosis of Mibelli. Br J Dermatol 2012; 166: 681-682.

DOI: https://doi.org/10.1111/j.1365-2133.2011.10626.x

Atzmony L, Lim YH, Hamilton C, Leventhal JS, Wagner A, Paller AS, et al. Topical cholesterol/lovastatin for the treatment of porokeratosis: a pathogenesis-directed therapy. J Am Acad Dermatol 2020; 82: 123-131.

DOI: https://doi.org/10.1016/j.jaad.2019.08.043

Li M, Li Z, Wang J, Ni C, Sun Z, Wilson NJ, et al. Mutations in the mevalonate pathway genes in Chinese patients with porokeratosis. J Eur Acad Dermatol Venereol 2016; 30: 1512-1517.

DOI: https://doi.org/10.1111/jdv.13653

Published

2021-02-16

How to Cite

Jägle, S., Juratli, H. A., Hickman, G., Süßmuth, K., Boente, M. C., Kopp, . J., Kirchmeier, P., Zimmer, A., Happle, R., Bourrat, E., Hamm, H., & Fischer, J. (2021). Porokeratosis Plantaris, Palmaris et Disseminata Caused by Con- genital Pathogenic Variants in the MVD Gene and Loss of Hetero­zygosity in Affected Skin. Acta Dermato-Venereologica, 101(2), adv00397. https://doi.org/10.2340/00015555-3753